CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Cemiplimab +3 moredrug
Likely dose
Prednisone 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04339062
NCT04339062Phase 2Completed
CompareCT.gov

Safety and Efficacy of Cemiplimab (PD-1 Blockade) in Selected Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (CONTRAC)

Dana-Farber Cancer Institute·interventional·Posted Apr 8, 2020·Updated Apr 23, 2025

In Brief

A Phase 2 clinical trial evaluating Cemiplimab, Everolimus, and 2 other interventions for Cutaneous Squamous Cell Carcinoma and Advanced Cancer. Completed, enrolled 12 participants across 1 site.

Detailed Summary

In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem cell transplant or kidney transplant. \- This research study involves the following drug(s): * Cemiplimab * Everolimus or Sirolimus * Prednisone

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCutaneous Squamous Cell Carcinoma, Advanced Cancer
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedApr 8, 2020
Enrollment StartNov 3, 2020
Primary CompletionJun 12, 2023
Study CompletionMar 1, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.2 years ago

Interventions

Cemiplimabdrug

Cemiplimab: via IV, flat predetermined dosage every 21 days.

Everolimusdrug

Everolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab

Sirolimusdrug

Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab

Prednisonedrug

40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapered dosing while receiving Cemiplimab